GILEAD SCIENCES, (GILD) Stock Research Free Stock Rating

Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for patients suffering from life-threatening diseases primarily in North America, Europe, and Australia. It focuses its research and clinical programs on anti-infectives. The company’s products include Viread, Emtriva, and Truvada, which are used for the treatment of human immunodeficiency virus infection in adults; AmBisome, an antifungal agent to treat serious invasive fungal infections caused by various fungal species; Hepsera, which is used for the treatment of chronic hepatitis B infection; Vistide, used for the treatment of cytomegalovirus retinitis; and DaunoXome, a liposomal formulation of the anticancer agent daunorubicin, for the treatment of AIDS-related Kaposi’s sarcoma. Its products also comprise Tamiflu, which is used for the prevention and treatment of influenza; and Macugen, for the treatment of neovascular age-related macular degeneration. Gilead sells its products primarily through wholesalers and distributors. The company has collaborative relationships with Bristol-Myers Squibb Company; Achillion Pharmaceuticals, Inc.; EyeTech Pharmaceuticals, Inc.; Fujisawa Healthcare, Inc.; GlaxoSmithKline; Japan Tobacco, Inc.; Pfizer, Inc.; F. Hoffmann-La Roche, Ltd.; and Sumitomo Pharmaceuticals Co., Ltd. Gilead was founded by Michael Riordan in 1987. The company is headquartered in Foster City, California.

Latest Headlines

Final Glance: Biotechnology companies (AP)

3 Reasons to Sell Best Buy Now (at Motley Fool)

Midday Glance: Biotechnology companies (AP)

9 Health-Care Stocks to Defend Your Portfolio (at Motley Fool)

Early Glance: Biotechnology companies (AP)

Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411 (PR Newswire)

Final Glance: Biotechnology companies (AP)

Data Demonstrating Significant Efficacy of Viread® in Treating Chronic Hepatitis B Published in New England Journal of Medicine (Business Wire)

Midday Glance: Biotechnology companies (AP)

US STOCKS-Market rises on Coca-Cola, other defensives (at Reuters)